295
Views
33
CrossRef citations to date
0
Altmetric
Methodology

Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data

, , , , , & show all
Pages 53-65 | Published online: 03 Jan 2019

References

  • BrewsterDHCoeberghJWStormHHPopulation-based cancer registries: the invisible key to cancer controlLancet Oncol20056419319515811615
  • PercyCStanekEGloecklerLAccuracy of cancer death certificates and its effect on cancer mortality statisticsAm J Public Health19817132422507468855
  • MantJWilsonSParryJClinicians didn’t reliably distinguish between different causes of cardiac death using case historiesJ Clin Epidemiol200659886286716828682
  • JohnsonCJHahnCGFinkAKGermanRRVariability in cancer death certificate accuracy by characteristics of death certifiersAm J Forensic Med Pathol201233213714221490500
  • SchaffarRRapitiERachetBWoodsLAccuracy of cause of death data routinely recorded in a population-based cancer registry: impact on cause-specific survival and validation using the Geneva Cancer RegistryBMC Cancer20131360924373194
  • SkuladottirHOlsenJHConditional survival of patients with the four major histologic subgroups of lung cancer in DenmarkJ Clin Oncol200321163035304012915592
  • HiekeSKleberMKönigCEngelhardtMSchumacherMConditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over TimeClin Cancer Res20152171530153625833308
  • ZaborECGonenMChapmanPBPanageasKSDynamic prognostication using conditional survival estimatesCancer2013119203589359223913639
  • XingYChangGJHuCYConditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysisCancer201011692234224120187100
  • HayduLEScolyerRALoSConditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma MetastasisJ Clin Oncol201735151721172928375785
  • RubioFJHongYSurvival and lifetime data analysis with a flexible class of distributionsJ Appl Stat2016431017941813
  • KarrisonTGUse of Irwin’s restricted mean as an index for comparing survival in different treatment groups–interpretation and power considerationsControl Clin Trials19971821511679129859
  • IrwinJOThe standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with miceJ Hyg194947218818915406758
  • RoystonPParmarMKThe use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStat Med201130192409242121611958
  • AndersenPKHansenMGKleinJPRegression analysis of restricted mean survival time based on pseudo-observationsLifetime Data Anal200410433535015690989
  • UnoHClaggettBTianLMoving beyond the hazard ratio in quantifying the between-group difference in survival analysisJ Clin Oncol201432222380238524982461
  • ZhaoLClaggettBTianLOn the restricted mean survival time curve in survival analysisBiometrics201672121522126302239
  • EngKHSeagleBLCovariate-Adjusted Restricted Mean Survival Times and CurvesJ Clin Oncol201735446546628129530
  • RoystonPParmarMKRestricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Med Res Methodol20131315224314264
  • BerksonJGageRPCalculation of survival rates for cancerProc Staff Meet Mayo Clin1950251127028615417650
  • EdererFAxtellLMCutlerSJThe relative survival rate: a statistical methodologyNatl Cancer Inst Monogr1961610112113889176
  • Pohar PermeMEstèveJRachetBAnalysing population-based cancer survival – settling the controversiesBMC Cancer201616193327912732
  • PermeMPStareJEstèveJOn estimation in relative survivalBiometrics201268111312021689081
  • MariottoABNooneAMHowladerNCancer survival: an overview of measures, uses, and interpretationJ Natl Cancer Inst Monogr201420144914518625417231
  • EstèveJBenhamouECroasdaleMRaymondLRelative survival and the estimation of net survival: elements for further discussionStat Med1990955295382349404
  • DanieliCRemontetLBossardNRocheLBelotAEstimating net survival: the importance of allowing for informative censoringStat Med201231877578622281942
  • de AngelisRSantMColemanMPCancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 – a population-based studyLancet Oncol2014151233424314615
  • AllemaniCWeirHKCarreiraHGlobal surveillance of cancer survival 1995–2009: analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries (CONCORD-2)Lancet20153859972977101025467588
  • BouvierAMRemontetLHedelinGConditional relative survival of cancer patients and conditional probability of death: a French National Database analysisCancer2009115194616462419569252
  • ShackLBryantHLockwoodGEllisonLFConditional relative survival: a different perspective to measuring cancer outcomesCancer Epidemiol201337444644823632048
  • Janssen-HeijnenMLGondosABrayFClinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancersJ Clin Oncol201028152520252820406936
  • YuXQBaadePDO’ConnellDLConditional survival of cancer patients: an Australian perspectiveBMC Cancer201212146023043308
  • GrafféoNCastellFBelotAGiorgiRA log-rank-type test to compare net survival distributionsBiometrics201672376076926821615
  • PavličKPermeMPOn comparison of net survival curvesBMC Med Res Methodol20171717928464839
  • CroninKAFeuerEJCumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survivalStat Med200019131729174010861774
  • LambertPCDickmanPWNelsonCPRoystonPEstimating the crude probability of death due to cancer and other causes using relative survival modelsStat Med2010297–888589520213719
  • LeeMCroninKAGailMHFeuerEJPredicting the absolute risk of dying from colorectal cancer and from other causes using population-based cancer registry dataStat Med201231548950022170169
  • CharvatHBossardNDaubisseLBinderFBelotARemontetLProbabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: a study of five common cancersCancer Epidemiol201337685786324063904
  • ElorantaSAdolfssonJLambertPCHow can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in SwedenCancer Causes Control201324350551523296456
  • GeskusRBData Analysis with Competing Risks and Intermediate StatesBoca RatonTaylor & Francis2016247
  • AndersenPKGeskusRBde WitteTPutterHCompeting risks in epidemiology: possibilities and pitfallsInt J Epidemiol201241386187022253319
  • BenichouJGailMHEstimates of absolute cause-specific risk in cohort studiesBiometrics19904638138262242416
  • AndersenPKDecomposition of number of life years lost according to causes of deathStat Med201332305278528523839860
  • HakamaMHakulinenTEstimating the expectation of life in cancer survival studies with incomplete follow-up informationJ Chronic Dis1977309585597903390
  • ChuPCWangJDHwangJSChangYYEstimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored ratesValue Health20081171102110918489497
  • BaadePDYouldenDRAnderssonTMEstimating the change in life expectancy after a diagnosis of cancer among the Australian populationBMJ Open201554e006740
  • DehbiHMRoystonPHackshawALife expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazardsBMJ2017357j225028546261
  • KalbfleischJDPrenticeRLThe Statistical Analysis of Failure Time Data2nd edHoboken, NJJohn Wiley2002
  • DiciccioTJEfronBBootstrap confidence intervalsStatist Sci1996113189228
  • Neighbourhood Renewal UnitThe English Indices of Deprivation 2004 (revised)LondonOffice for the Deputy Prime Minister2004
  • WoodsLMRachetBColemanMPChoice of geographic unit influences socioeconomic inequalities in breast cancer survivalBr J Cancer20059271279128215798765
  • Diez RouxAVInvestigating neighborhood and area effects on healthAm J Public Health200191111783178911684601
  • BelotARemontetLRachetBDescribing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based dataClin Epidemiol20181056157329844706
  • ZamboniBAYothersGChoiMConditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07J Clin Oncol201028152544254820406942
  • FagerlinAZikmund-FisherBJUbelPAHelping patients decide: ten steps to better risk communicationJ Natl Cancer Inst2011103191436144321931068
  • HoriguchiMCroninAMTakeuchiMUnoHA flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trialsStat Med201837152307232029682762
  • TianLFuHRubergSJUnoHWeiLJEfficiency of two sample tests via the restricted mean survival time for analyzing event time observationsBiometrics201874269470228901017
  • RemontetLBossardNBelotAEstèveJFrench network of cancer registries FRANCIMAn overall strategy based on regression models to estimate relative survival and model the effects of prognostic factors in cancer survival studiesStat Med200726102214222816900570
  • CharvatHRemontetLBossardNA multilevel excess hazard model to estimate net survival on hierarchical data allowing for nonlinear and non-proportional effects of covariatesStat Med201635183066308426924122
  • Luque-FernandezMABelotAQuaresmaMMaringeCColemanMPRachetBAdjusting for overdispersion in piecewise exponential regression models to estimate excess mortality rate in population-based researchBMC Med Res Methodol201616112927716079
  • PutterHFioccoMGeskusRBTutorial in biostatistics: competing risks and multi-state modelsStat Med200726112389243017031868
  • BhaskaranKHamoudaOSannesMChanges in the risk of death after HIV seroconversion compared with mortality in the general populationJAMA20083001515918594040
  • Mcdavid HarrisonKLingQSongRHallHICounty-level socioeconomic status and survival after HIV diagnosis, United StatesAnn Epidemiol2008181291992719041591
  • ElieCde RyckeYJaisJLandaisPAppraising relative and excess mortality in population-based studies of chronic diseases such as end-stage renal diseaseClin Epidemiol2011315716921607017
  • NordioMLimidoAMaggioreUSurvival in patients treated by long-term dialysis compared with the general populationAm J Kidney Dis201259681982822361043
  • Trébern-LaunayKGiralMDantalJFoucherYComparison of the risk factors effects between two populations: two alternative approaches illustrated by the analysis of first and second kidney transplant recipientsBMC Med Res Methodol201313110223915191
  • GibertoniDMandreoliMRucciPExcess mortality attributable to chronic kidney disease. Results from the PIRP projectJ Nephrol201629566367126498295
  • NelsonCPLambertPCSquireIBJonesDRRelative survival: what can cardiovascular disease learn from cancer?Eur Heart J200829794194718326008
  • AlabasOAGaleCPHallMSex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART RegistryJ Am Heart Assoc2017612e00712329242184
  • HardieKHankeyGJJamrozikKBroadhurstRJAndersonCTen-year survival after first-ever stroke in the Perth community stroke studyStroke20033481842184612843343
  • BrinkhofMWBoulleAWeigelRMortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortalityPLoS Med200964e100006619399157
  • ChenPYTsiatisAACausal inference on the difference of the restricted mean lifetime between two groupsBiometrics20015741030103811764241
  • ZhangMSchaubelDEDouble-robust semiparametric estimator for differences in restricted mean lifetimes in observational studiesBiometrics2012684999100922471876
  • CalkinsKLCananCEMooreRDLeskoCRLauBAn application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug useBMC Med Res Methodol20181812729523081
  • MansourvarZMartinussenTEstimation of average causal effect using the restricted mean residual lifetime as effect measureLifetime Data Anal201723342643827037915